SCHEMBL5664002

SCHEMBL5664002

NCC#Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)nc1N

nearest known ligand 0.51

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
POLG P54098 2/20 0.51
POLB P06746 3/20 0.50
P2RY2 P41231 2/20 0.49
P2RY4 P51582 2/20 0.49
P2RY6 Q15077 2/20 0.49
DTYMK P23919 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10022245 1.00 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL22327108 1.00 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL5664015 1.00 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL8417580 0.93 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL8417572 0.93 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL18952763 0.92 POLG (0.50) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL18790022 0.91 POLB (0.50) POLB
SCHEMBL17124949 0.91 POLG (0.49) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL10022896 0.91 POLB (0.47) POLBP2RY2P2RY4P2RY6
SCHEMBL1332964 0.91 POLG (0.51) POLGPOLBP2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250369043-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS INC (US) 2025-12-04 US disclosed
US-12378600-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2025-08-05 US disclosed
CN-119662792-A Adaptors and methods for optical detection and sequencing 阿尔缇玛基因组学公司 2025-03-21 CN disclosed
US-20240263216-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS, INC. 2024-08-08 US disclosed
US-11946097-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2024-04-02 US disclosed
US-11807851-B1 Modified polynucleotides and uses thereof ULTIMA GENOMICS, INC. (US) 2023-11-07 US disclosed
US-20220282309-A1 LINKERS AND METHODS FOR OPTICAL DETECTION AND SEQUENCING ULTIMA GENOMICS, INC. 2022-09-08 US disclosed
US-11377680-B2 Linkers and methods for optical detection and sequencing ULTIMA GENOMICS, INC. (US) 2022-07-05 US disclosed
US-7053208-B2 Dioxetane labeled probes and detection assays employing the same APPLERA CORPORATION (US) 2006-05-30 US disclosed
US-6451531-B1 A FIRST BIOLOGICAL MOIETY SELECTED FROM THE GROUP CONSISTING OF A NUCLEIC ACID, A PEPTIDE NUCLEIC ACID, A PROTEIN, A STEROID AND A CARBOHYDRATE, SAID BIOLOGICAL MOIETY BEARING A 1,2-DIOXETANE PRECURSOR BOUND THERETO, SUCH THAT, UPON TROPIX, INC. 2002-09-17 US disclosed
US-20020106687-A1 Dioxetane labeled probes and detection assays employing the same APPLIED BIOSYSTEMS, INC. 2002-08-08 US disclosed
EP-0765401-B1 PRIMER EXTENSION MASS SPECTROSCOPY NUCLEIC ACID SEQUENCING METHOD AMERSHAM PHARM BIOTECH UK LTD (GB) 2001-02-21 EP disclosed
US-6063574-A Dioxetane labeled probes and detection assays employing the same TROPIX, INC. (US) 2000-05-16 US disclosed
US-5849542-A Primer extension mass spectroscopy nucleic acid sequencing method AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) 1998-12-15 US disclosed
US-5800999-A Dioxetane-precursor-labeled probes and detection assays employing the same TROPIX, INC. (US) 1998-09-01 US disclosed
EP-0251786-B1 Alkynylamino-nucleotides DU PONT (US) 1994-11-30 EP disclosed
US-5151507-A Alkynylamino-nucleotides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-09-29 US disclosed
EP-0369360-A2 Differentiation of nucleic acid segments on the basis of nucleotide differences E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-05-23 EP disclosed
US-4879214-A Differentiation of nucleic acid segments on the basis of nucleotide differences E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020106687-A1 Dioxetane labeled probes and detection assays employing the same DCLRE1A, DDB1, CYP4X1 POLG 913/4885POLB 826/4885P2RY2 4732/4885
US-11807851-B1 Modified polynucleotides and uses thereof PNKP, CPSF1, DCLRE1B POLG 337/4885POLB 296/4885P2RY2 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.